Clinical Trials Browser

Phase 1 × darolutamide × Genitourinary × Clear all

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

300 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT07103018 2026-03-23

STRIKE-001

Phase 1 Recruiting

144 enrolled

Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

10 enrolled

Genitourinary

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Phase 1 Active not recruiting

9 enrolled

Genitourinary

Prostatic Neoplasms

NCT05938270 2026-02-24

ASCERTAIN

Phase 1 Recruiting

120 enrolled

Genitourinary

Prostatic Neoplasms

NCT05997615 2026-02-24

AMX-500

Phase 1 Recruiting

390 enrolled

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07140900 2026-02-13

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Phase 1 Recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Phase 1 Recruiting

30 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07244341 2026-02-04

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Recruiting

60 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05519449 2026-01-20

ENGAGER-PSMA-01

Phase 1 Recruiting

272 enrolled

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01784757 2021-03-17

ARAFOR

Phase 1 Completed

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT03237416 2018-11-06

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Phase 1 Completed

15 enrolled

Genitourinary

Prostatic Neoplasms